Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that decreases the amount of acid produced in the stomach.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Reduction of risk of NSAID-associated gastric ulcers in patients at continued risk.
* Pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
## Adult Dosing
* **Erosive Esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks. A subsequent 8-week course may be considered for patients who have not healed.
* **Maintenance of Healing of Erosive Esophagitis:** 40 mg orally once daily.
* **Symptomatic GERD:** 20 mg orally once daily for up to 4 weeks.
* **Reduction of NSAID-Associated Gastric Ulcers:** 40 mg orally once daily.
* For healing: up to 8 weeks.
* For prevention: duration of NSAID therapy, typically up to 1 year.
* **Zollinger-Ellison Syndrome:** 40 mg orally or intravenously twice daily. Doses may be increased to 240 mg per day (given as 120 mg IV infusion over 30 minutes every 8 hours or divided into 40 mg oral doses three times daily).
## Pediatric Dosing
* **Erosive Esophagitis (GERD-associated):**
* **12 to 17 years:** 40 mg orally once daily for up to 8 weeks.
* **5 to 11 years:** 20 mg orally once daily for up to 8 weeks. For patients requiring a higher dose, consider 40 mg orally once daily.
* **Under 5 years:** Limited data. Dosing is not established.
## Dose Adjustments
* **Hepatic Impairment:** For oral formulations, maximum dose is 20 mg once daily. No dose adjustment necessary for IV formulation in mild to moderate hepatic impairment. Data for severe hepatic impairment is limited.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
## Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain, flatulence, dizziness.
* **Serious:** *Clostridium difficile*-associated diarrhea, bone fracture (hip, wrist, spine), hypomagnesemia (can be asymptomatic or manifest as tetany, seizures, tremors, irregular heartbeat), vitamin B12 deficiency, fundic gland polyps.
## Key Drug Interactions
* **Drugs requiring gastric acid for absorption:** Pantoprazole can decrease absorption of drugs like ketoconazole, itraconazole, posaconazole, and certain HIV protease inhibitors (e.g., atazanavir, nelfinavir). Separate administration by several hours if possible.
* **Methotrexate:** PPIs may increase methotrexate levels. Consider drug-free intervals or dose reduction of methotrexate if clinically indicated.
* **CYP2C19 Substrates:** Pantoprazole can inhibit CYP2C19. Use with caution with drugs like clopidogrel, cilostazol, and certain antidepressants.
## Monitoring
* Monitor for signs and symptoms of *Clostridium difficile* infection (diarrhea, abdominal cramping, fever).
* Consider monitoring serum magnesium levels, especially with prolonged therapy (>3 months) or concurrent use of other magnesium-depleting drugs (e.g., diuretics).
* Monitor for signs of bone fracture with long-term therapy.
* Assess for B12 deficiency symptoms with long-term therapy.
## Clinical Pearls
* Oral pantoprazole should be taken at least 30 minutes before a meal.
* Oral suspension should be prepared according to manufacturer instructions.
* IV administration requires reconstitution and further dilution. Ensure compatibility with other IV admixtures.
* Long-term PPI use is associated with increased risks of fractures, *C. difficile* infection, and hypomagnesemia. Use the lowest effective dose for the shortest duration necessary.
***
*Disclaimer: This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and relevant clinical guidelines for complete details and to verify dosing and safety information before patient use.*
